You are here: Industry Insights > ACE2

News List

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins prnasia
September 28, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study...
Study reveals mechanisms of increased infectivity, antibody resistance of SARS-CoV-2 variants: SARS-CoV-2 spike variants take different paths to result in a more infectious and resistant COVID virus firstwordpharma
June 30, 2021
Combining structural biology and computation, a Duke-led team of researchers has identified how multiple mutations on the SARS-CoV-2 spike protein independently create variants that are more transmissible and potentially resistant to antibodies.
Virus that causes COVID-19 can find alternate route to infect cells worldpharmanews
June 25, 2021
Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection.
Mithra Completes Recruitment of Covid-19 Phase II Study firstwordpharma
June 18, 2021
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has completed recruitment of the Coronesta Phase II, aiming to assess the protective role of Estetrol in Covid-19 infection.
Researchers Show How COVID-19 Virus Triggers Immune Signaling "Storm" prnewswire
May 17, 2021
Researchers have discovered new ways in which the COVID-19 virus causes human immune cells to overreact, a deadly part of the disease.
Hormone drugs may disarm COVID-19 spike protein and stop disease progression worldpharmanews
March 24, 2021
Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the ...
Kyushu University Confirms HORIUCHI L-FUCOIDAN Inhibits Binding between ACE2 and Virus Spike Protein (Derived from COVID-19) prnasia
February 26, 2021
FCC Horiuchi Co., Ltd. based in Kurume City, Fukuoka Prefecture, western Japan, has conducted an experiment in inhibiting binding between ACE2 and virus spike protein using HORIUCHI L-FUCOIDAN, manufactured by the ...
ImmunityBio Simulations give clue to why South African strain of SARS-CoV-2 is rapidly spreading expresspharma
January 20, 2021
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2.
ACE2 protein protects against severe COVID-19 worldpharmanews
December 18, 2020
Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stronger immune response, according to new research from a University of Alberta-led team.
Scientists identify synthetic mini-antibody to combat COVID-19 worldpharmanews
November 06, 2020
The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

Previous page 1 2 Next page